Fig. 3. The PKC inhibitor abrogates MAPK activation, growth arrest and myosin expression. (A) Immunoblots of total lysates from RD cells, either untreated (C) or treated with TPA for 30 minutes, pre-treated (6 hours) with 60 nM PKC inhibitor Ro320432 (Ro) in the presence and absence of TPA, using the antibodies described in the legend for Fig. 1. (B) Growth curve of RD cells either untreated (C) or treated with TPA for different times (0, 1, 3 and 6 days, TPA) and after pre-treatment with the PKC inhibitor (Ro, Ro + TPA). Each value represents the mean±s.e.m. of three samples. (C) Immunoblots of total lysate from cells, either untreated (C) or treated with TPA for 6 days (TPA) and pre-treated with Ro320432, in the absence or presence of TPA, (Ro, Ro + TPA) using anti-myosin heavy chain (MHC) antibody. The data shown are representative of three independent experiments.